Non-invasive Placental Chromosome Exploration of Intrauterine Growth Restriction

Launched by UNIVERSITY HOSPITAL, BORDEAUX · Aug 20, 2021

Keywords

ClinConnect Summary

This clinical trial is studying a new way to check the chromosomes in the placenta of pregnant women whose babies are not growing as expected, specifically those whose growth is below the 3rd percentile. The goal is to find out if there are any genetic issues with the placenta that could be affecting the baby's growth, using a non-invasive method alongside a procedure called amniocentesis, which involves taking a small sample of the amniotic fluid for testing.

To be eligible for this trial, participants should be women over 18 years old, receiving care at the DDIANE fetal medicine center in Bordeaux, and have a fetus diagnosed with intrauterine growth restriction (IUGR) that is below the 3rd percentile, confirmed by an ultrasound. They must be at least 16 weeks pregnant and agree to undergo amniocentesis for further testing. Participants can expect to have their placenta's chromosomes studied to gain insight into potential causes of the growth restriction, which could help in managing their pregnancy better. It's important to note that women who do not consent to the amniocentesis or have other complications related to IUGR might not be eligible for this study.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • over 18 years old,
• • treated in the DDIANE fetal medicine centre at the Bordeaux University Hospital,
• • having a fetus with IUGR diagnosis below the 3rd percentile (after reference medical ultrasound),
• • from 16 weeks of amenorrhea or more,
• • accepting an Invasive Prenatal Diagnosis by amniocentesis with array comparative genomic hybridization
• Exclusion Criteria:
• Childbearing women who:
• • do not accept a non-invasive prenatal diagnosis (amniocentesis)
• • have a fetus with non-isolated IUGR (associated with other ultrasound signs)
• • do not consent to participate in the research protocol